GHP Aug 2017

20 GHP / August 2017 , The CALM (Controlling and Lowering Blood Pressure with MobiusHD) 2 trial is a multi-centre, prospective, randomised, double-blind, sham- controlled pivotal study designed to evaluate the safety and effectiveness of the MobiusHD System. The company will evaluate patients from select locations throughout the United States whose hypertension remains uncontrolled despite using three or more anti-hypertensive pharmacologic therapies. VDI also intends to conduct the CALM 2 trial in certain European countries following appropriate regulatory authorisation. “The rigor and scientific focus of the Calm 2 trial has been crafted and improved from much of what we learned from prior studies. Calm 2 will offer patients a therapeutic alternative and a level of medical monitoring to which they otherwise would never have access outside of a clinical trial,” said Bryan Williams co-principal investigator The Treatment of Resistant Hypertension Vascular Dynamics, Inc., (VDI) a privately heldmedical device company developing novel solutions for the treatment of hypertension, on August 15th announced that the United States Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) application, to initiate its pivotal trial for its MobiusHD ® System for the treatment of resistant hypertension. of the Calm 2 trial and Chair of Medicine at University College London and Director of the NIHR UCLH/UCL Biomedical Research Centre and Director of Research, at UCL Hospitals. He is chairman-elect of the European Council on Hypertension of the European Society of Cardiology. “In clinical practice, we are regularly faced with those hypertension patients who simply do not respond to medication or lifestyle changes. Initiating this trial is an important step toward identifying additional viable treatments to help this large population of patients,” said Gregg Stone, MD, co-principal investigator of the CALM 2 trial and director of cardiovascular research and education for Columbia University Medical Centre/New York-Presbyterian Hospital and co-director of medical research and education at the Cardiovascular Research Foundation. The company has been chosen as a participant in the FDA’s Expedited Access Pathway (EAP) programme, a focused initiative to significantly accelerate access for US patients and their physicians to innovative medical treatments. VDI is also one of only nine companies chosen for the FDA’s Early Feasibility Study Investigational Device Exemptions (IDE) Pilot Programme, which enables companies to conduct smaller- scale studies under the guidance of the agency in the United States to meet the requirements for an earlier pathway toward approval. “Initiating the CALM 2 trial is an important milestone for Vascular Dynamics, as it allows us the opportunity to demonstrate the potential utility of our technology in a significant patient population,” said Robert Stern, president and CEO of Vascular Dynamics. “With our participation in both the EAP and IDE programmes, we also have the unique opportunity to work closely with the FDA to ensure a more rapid start to the trial while still maintaining the high standards of safety, efficacy and scientific validity required by the programme” he added. The MobiusHD System, a minimally-invasive system, capitalises on the ability of the body’s baroreceptor mechanism, to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby increase the body’s natural response to lower blood pressure, through vasodilation. About resistant hypertension Hypertension, or elevated blood pressure, is a common medical condition that currently affects one billion people worldwide. (1) If left untreated, hypertension can cause life-threatening problems, including heart attack, aneurysm, stroke or kidney failure. Patients with hypertension can often reduce their risk factors by making lifestyle changes such as losing weight, quitting smoking, and increased exercise. In cases with advanced hypertension, medical therapies may be prescribed.